Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when LL-37 crosses your target, drops, or sets a new tracked low—without daily noise.

Price scope Alert me Target per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence 46 certificate records for LL-37 products, from 26 vendors 23 reference a report on the testing laboratory's own system · 18 have a laboratory lookup that answered when last checked · 43 match a vendor product page at the same address

Status

Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area

Immune / inflammation research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Aliases

No major aliases are tracked for this profile yet.

Signal depth

Medium

No FDA label signal · 98 trials · 4355 PubMed results

Promising

Research evidence

LL-37 has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

LL-37 has 15 name-matched clinical trials (highest phase: Phase 4) and 4355 PubMed-indexed publications and is not FDA-approved. 2 trials have posted results.

Human data

Phase 3

Trial quality

Randomized

Outcomes

Clinical outcomes

Replication

Meta-analysis

Literature

Top-tier journals

PHASE4 · Randomized Association of Cathelicidin and Vitamin D Levels With the Category and Course of COPD PHASE2 · Randomized Efficacy of LL-37 Cream on Bacteria Colonization, Inflammation Response and Healing Rate of Diabetic Foot Ulcers PHASE2 Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD The Journal of Experimental Medicine · 1,240 citations Ll-37, the Neutrophil Granule–And Epithelial Cell–Derived Cathelicidin, Utilizes Formyl Peptide Receptor–Like 1 (Fprl1) as a Receptor to Chemoattract Human Peripheral Blood Neutrophils, Monocytes, and T Cells The FASEB Journal · 1,136 citations Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up‐regulated in myeloid cells by 1,25‐dihydroxyvitamin D 3 Biochimica et Biophysica Acta (BBA) - Biomembranes · 1,049 citations LL-37, the only human member of the cathelicidin family of antimicrobial peptides

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-14 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What LL-37 is

LL-37 is a human antimicrobial peptide involved in innate immune signaling. In peptide-market contexts it is usually discussed in relation to host defense, inflammation, or tissue response.

Why it matters

It adds a genuine immune-facing profile to the library and helps keep the peptide catalog from collapsing into only obesity and recovery topics.

Regulatory context

LL-37 is not an FDA-approved peptide medicine for consumer use in the United States.

Practical reading note

Immune-related compounds are especially easy to overstate, so the most useful framing is what biological lane a peptide belongs to, not whether a vendor presents it as a broad health solution.